Developing a new treatment to protect hearing from certain antibiotics
ANALYTICAL METHOD DEVELOPMENT, VALIDATION AND STABILITY STUDY OF ORC-13661
This study is testing a new drug called ORC-13661 to see if it can help protect your hearing and balance while you take certain antibiotics that can sometimes cause damage to your inner ear. If it works, it could make it safer for you to use these antibiotics when you need them for serious infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwest Research Institute NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10972995 on NIH RePORTER |
What this research studies
This research focuses on developing a new drug, ORC-13661, which aims to protect inner ear hair cells from damage caused by aminoglycoside antibiotics (AGs). These antibiotics are effective against serious infections but can lead to hearing loss and balance issues due to their toxic effects on the inner ear. The study will involve validating the effectiveness of ORC-13661 in preventing these side effects, potentially allowing for safer use of AGs in patients. Patients may benefit from this research if the new treatment proves successful in preserving their hearing and balance while receiving necessary antibiotic therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require aminoglycoside antibiotics for serious infections and are at risk of ototoxicity.
Not a fit: Patients who do not require aminoglycoside antibiotics or have pre-existing conditions that prevent them from using these antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could allow patients to receive effective antibiotic treatment without the risk of hearing loss or balance issues.
How similar studies have performed: While the approach of developing protective therapies against antibiotic-induced ototoxicity is promising, it is still relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Kansas City, United States
- Midwest Research Institute — Kansas City, United States (Active)
Researchers
- Principal investigator: Slade, Desmond — Midwest Research Institute
- Study coordinator: Slade, Desmond
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.